FDA Approves Gene Therapy

 In Advocacy, News
On November 22, 2022, the U.S. Food and Drug Administration (FDA) approved the first gene therapy treatment for hemophilia!
Hemgenix is a one-time gene therapy product given as a single dose by IV infusion for qualifying hemophilia B patients over the age of 18. Learn more from the FDA by clicking here.

Leave a Comment

Start typing and press Enter to search